Short-term effect of COVID-19 lockdowns on atmospheric CO2, CH4 and PM2.5 concentrations in urban environment.

The COVID-19 pandemic has changed all areas of human activity as it forced the authorities around the world to enact unprecedented restrictions such as "lockdowns". The low economic activity reduced the anthropogenic impact on the environment, in particular, greenhouse gases and aerosols emissions were decreased. However, the associated change in air quality is difficult to directly observe and quantify, since concentrations of these components in urban areas are affected by many other factors. In this work statistical analysis of atmospheric CO2, CH4 and PM2.5, measured in 2017-2020 in the city of Ekaterinburg, Russia, are presented. A detailed focus was made on the lockdown period from March 28 to April 30, 2020. A significant decrease in concentrations and inter-hourly variations of all studied components were observed only in the short "self-isolation" period from April 6 to April 8. The anthropogenic origin of this effect, primarily associated with the reduction in vehicular traffic, was concluded from mean diurnal cycles and air temperature correlations of all components. A decrease in the difference between measured and background CO2 and CH4 mole fractions was also found during this period. The difference was 1.3±0.2 ppm for CO2 and 8±4 ppb for CH4, which was many times lower than during any other observed periods, suggesting a short-term effect of lockdown restrictions. Overall, a negative impact on the atmosphere quickly resumed after the recovery of economic activity. The approaches in this study can be used to detect weak fluctuations of atmospheric components in other urban territories.

Historical epidemiology of hepatitis C virus in select countries-volume 4.

Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country-specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.

Strategies to manage hepatitis C virus infection disease burden-Volume 4.

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets-"WHO Targets" (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.

Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV-related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high-treatment rate will contribute to a reduction in total cases and HCV-related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV-related morbidity and mortality.

Current assessment of integrated content of long-lived radionuclides in soils of the head part of the East Ural Radioactive Trace.

Based on the datasets obtained during investigations from 2003 to 2012, the spatial distributions of (90)Sr, (137)Cs, and (239,240)Pu content in the soils of the head part of the East Ural Radioactive Trace (EURT) were mapped using the geographic information system ArcGIS. Taking into account the presence of spatial autocorrelation and anisotropy in the source data, an ordinary kriging method was applied to interpolate values of radionuclide contamination density at unsampled places. Further geostatistical data analysis was performed to determine the basic parameters of spatial dependencies and to integrally assess the contamination by long-lived radionuclides in soils of the central, east peripheral, and west peripheral parts of the trace. This analysis was based on simplified geometric models (sector- and rectangle-shaped areas). The Monte Carlo method was used to quantitatively assess the uncertainty of the values for the integrated quantities resulting from the statistical errors of the source data approximation.

Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report.

BACKGROUND: Patients with concomitant hepatitis C (HCV) and B (HBV) infection are difficult to treat due to lack of medicines that control these viral infections and the high risk of hepatocellular carcinoma. Currently, there are insufficient data regarding the therapeutic effect of interleukin-2 (IL-2) during chronic viral infection, but this cytokine has shown antineoplastic activity and may have also an antiviral effect. CASE REPORT: We present the case of a 44-year-old patient with hemophilia A, HBV and HCV related compensated liver cirrhosis (Child-Pugh A) with several zones in the liver, highly suspicious for hepatocellular carcinoma. The patient was treated with low-dose intermittent subcutaneous IL-2 immunotherapy, followed by standard therapy with pegasys and copegus. During 23 months' follow-up, no tumour progression occurred, and the patient remained in Child-Pugh A stage. The initial HCV and HBV loads were significant (538,207 IU/ml) and minimal (825 copies/ml), respectively. The patient was treated with intermittent subcutaneously applied low-dose IL-2 cycles for ten months. HBV DNA and HCV RNA were undetectable 3 months after the last IL-2 cycle. After cessation of IL-2 therapy, the patient received standard antiviral treatment with pegasys and copegus. Nine months later, a slight reactivation of viruses was observed: HBV DNA was 18,600 copies/ml and HCV RNA was 58 IU/ml. Twenty-three months after the last IL-2 treatment (at the time of writing), the patient is alive and in a good clinical condition. CONCLUSION: The decrease of HBV and HCV nucleic acids during immunotherapy with IL-2 predicts a possible new therapeutic option for these chronic viral infections.

[Biotechnological synthesis of ribavirin. Effect of ribavirin and its various combinations on the reproduction of Vaccinia virus]. / Biotekhnologicheskii sposob polucheniia ribavirina. Deistvie ribavirina i nekotorykh ego kombinatsii na reproduktsiiu virusa ospovaktsiny (Vaccinia virus).

The biotechnological method of synthesis of ribavirin, vidarabin, and 6-azauridine by the use of immobilized recombinant enzymatic preparations of nucleoside phosphorylase was improved. The effect of ribavirin and its combinations with the other synthesized nucleosides on the reproduction of Vaccinia virus was studied using cultures of Vero cells. The combination of ribavirin and vidarabin was shown to provide an antiviral effect at lesser concentrations than when these compounds were taken separately. The English version of the paper: Russian Journal of Bioorganic Chemistry, 2004, vol. 30, no. 6; see also http://www.maik.ru.

[Chemical and chemico-enzymatic synthesis of alpha-thiotriphosphate nucleosides]. / Khimicheskii i khimiko-fermentativnyi sintez alpha-tiotrifosfatov nukleozidov.

New methods of chemical and chemoenzymatic synthesis of nucleoside 5'-thiophosphates and 5'-alpha-thiotriphosphates are developed. The 5'-alpha-thiotriphosphates are used as substrates both in template-dependent enzymatic PCR synthesis and in a T7-RNA transcription polymerase system. The English version of the paper: Russian Journal of Bioorganic Chemistry, 2003, vol. 29, no. 6; see also http://www.maik.ru.

Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients--a pilot study.

BACKGROUND/AIMS: We evaluated the effect of immunomodulatory treatment with levamisole in HBeAg positive or anti-HBe positive patients with chronic HBV infection and ongoing viral replication. The majority of patients had an expected poor response to IFN-alpha. METHODOLOGY: Twenty-five viremic patients (15 males and 10 females) with chronic HBV infection were treated with Levamisole for 12 months or until negative serum HBV DNA occurred for at least 3 months. Viral replication and aminotransferase activity were controlled at the end of 3, 6, 9 and 12 months during the treatment. RESULTS: A decrease of serum HBV DNA was noted when serum HBV DNA levels before and after treatment with levamisole were compared, by t-test for dependent samples (p < 0.05). There was a significant reduction of ALT activity, too. HBV DNA fell below the detection limit of our assay at the end of 3, 6, 9 and 12 months in 7, 7, 8 and 10 of the patients, respectively. In 3 of 16 initially HBeAg positive patients, seroconversion to anti-HBe antibody occurred. At the end of 12 months 10 patients were with negative serum HBV DNA and normal ALT activity. Two of them lost HBsAg during the treatment. Ten patients were without any effect from the therapy. The potential responder initially is anti-HBe positive, with low serum HBV DNA < 500 pg/ml and low ALT activity (< 3 times the upper limit of normal). CONCLUSIONS: Immunomodulation with levamisole may benefit some patients with chronic ongoing viral replication including patients with expected poor response to IFN-alpha. This treatment could be used as an alternative therapeutic schedule in patients contraindicated for IFN-alpha, and also because it lowers treatment costs.

Headache and analgesic use in Sweden.

In this study, patterns of analgesic use among persons with headache in the general Swedish population were analyzed in association with health factors, health care utilization, sociodemographic factors, and life-style. Data from the Swedish Survey of Living Conditions for the 2-year period 1988 through 1989 were used. In this survey, a probability sample of the Swedish population aged 16 years and older was interviewed. Persons with headache were identified by the question, "Have you (during the last 2 weeks) had recurrent headache or migraine?" Analgesic use was defined by the question, "Have you (during the last 2 weeks) used prescription or nonprescription analgesics?" Persons who answered both these questions were included in the present study, yielding a study population of 11,975 persons. Sixteen percent of all women and 8.2 percent of all men reported headache. Seventy-four percent of all women with headache reported analgesic use as compared to 64% of all men with headache. Analgesic use increased with increasing age among women but not men. While few of the studied factors were associated with analgesic use among persons with headache, the associations found differed by gender. Poor social network and musculoskeletal pain were associated with analgesic use among men with headache; age, being underweight, and visits to a physiotherapist were associated with analgesic use among women with headache. Those studying medication use among persons with headache might consider including these factors in future studies to help better understand the mechanisms behind the decision to use or avoid analgesics.

Prescription and nonprescription analgesic use in Sweden.

OBJECTIVE: To analyze patterns of prescription and nonprescription analgesic use in the general Swedish population, in association with predisposing factors, enabling factors, need, and health behavior. DESIGN: Cross-sectional interview survey. SETTING: The Swedish Surveys of Living Conditions for the 2-year period 1988-1989. PARTICIPANTS: A probability sample of all inhabitants of Sweden aged 18-84 years (n = 11996). MAIN OUTCOME MEASURES: Prescription and nonprescription analgesic use during a 2-week period. RESULTS: Women reported use of analgesics both with and without prescriptions to a greater extent than did men. Among women, 12.2% reported prescription analgesic use and 30.4% reported nonprescription analgesic use. The corresponding proportions among men were 7.2% and 20.0%, respectively. In the descriptive analyses, prescription analgesic use was most common among persons aged 45 years and older, while use of nonprescription analgesics was most common in people aged 18-44 years. The polychotomous logistic regression analyses showed that headache and musculoskeletal pain were strongly associated with prescription analgesic use to a similar extent among men and women. Headache was associated with nonprescription analgesic use among men and women, but a gender difference was found in the association between musculoskeletal pain and nonprescription analgesic use. Women with musculoskeletal pain used nonprescription analgesics to a greater extent than did men with musculoskeletal pain. Poor health--measured as self-perceived health status and physical function--and high use of health care were related only to prescription analgesic use. Smoking and being overweight were associated with prescription analgesic use among men and with nonprescription analgesic use among women; alcohol consumption was associated with both types of analgesic use only among women. CONCLUSIONS: This study shows that men and women differ in their choice between prescription and nonprescription analgesics and that the choice between prescription and nonprescription analgesics is influenced by an individual's pain, self-perceived health, and lifestyle.

Synthesis and serological characterization of L-glycero-alpha-D-manno-heptopyranose-containing di- and tri-saccharides of the non-reducing terminus of the Escherichia coli K-12 LPS core oligosaccharide.

Synthesis of the title trisaccharide was accomplished by sugar chain extension starting from the non-reducing terminus: coupling of Glcp NAc with LD-Hepp, then adding Glcp-OAll. An alternative route started from the reducing end: coupling of LD-Hepp with Glcp-OAll, then addition of Glcp NAc. In the synthesis of the title disaccharide a modification of the first approach was employed. The allyl glycosides were coupled with cysteamine, activated with thiophosgene and conjugated to bovine serum albumin (BSA). The neoglycoconjugates obtained were used in immunochemical studies of monoclonal and polyclonal antibodies directed against Escherichia coli K-12 lipopolysaccharide.

Clinical significance of serum HBeAg and HBV-DNA-specific values of virus replication in chronic hepatitis-B virus infection.

The prevalence of serum HBV-DNA and that of HBeAg was evaluated in 44 subjects (27 males and 17 females) aged between 3 and 59 years. They were divided in two groups: (A) chronic asymptomatic HBsAg carriers; and (B) chronic HBsAg carriers with a history of HBV infection. The patients had been chronic HBV carriers between 8 months and 15 years. All underwent clinical and biochemical evaluation. The serological markers of HBV infection were tested using ABBOTT assay kits. The serum HBV-DNA was quantified using a hemiluminiscence molecular hybridization assay (Digene-Murex). HBV-DNA+ were 13 patients (29.55 +/- 6.88%). The highest level of viral replication (up to 50%) was measured in the patients aged from 3 to 29 years while in the others a 3 to 4-fold decrease of the viral replication was detected. HBV-DNA+ were 8 (23.53 +/- 6.39%) of the chronic asymptomatic hepatitis B carriers and 5 (50.00 +/- 7.5%) of the chronic HBV carriers with former acute hepatitis B infection. Similar results were obtained for the other index of viral replication--HBeAg/anti-HBe. Eight (23.53 +/- 6.39%) patients from group I and 4 (40.00 +/- 7.38%) patients from group II were HBeAg+ while anti-HBe+ were 26 (76.47 +/- 6.39%) and 6 (60.00 +/- 7.38%) patients from group I and II, respectively, i.e., about a quarter of the chronic asymptomatic HBsAg carriers and half of the chronic HBV carriers that had had an acute hepatitis B virus infection had HBV replication in their bodies. HBeAg+ patients had high levels of serum HBV-DNA (625.70-3328.00 pg/ml) which indicated extremely intensive viral replication. The presence of HBeAg and especially of HBV-DNA as markers of viral replication in chronic asymptomatic HBsAg carriers and chronic HBsAg carriers with a prior acute hepatitis B virus infection provide important information for the clinical decisions.

Differentiation of core gene products of the hepatitis B virus in infected liver tissue using monoclonal antibodies.

Hepatitis B virus (HBV) core gene translational products were localised previously in the cytoplasm and/or in the nuclei of infected cells. We investigated in naturally infected human hepatocytes whether this variation in the subcellular expression is due to differences in the presence of assembled core particles and other core gene derived proteins, the expression of HBeAg and the processing of liver tissue. By immunostaining of liver specimens infected with HBeAg-positive and HBeAg-minus variants of HBV, using monoclonal antibodies specific for assembled core particles and for various epitopes on denatured core protein, it was shown that virtually all immunoreactive core gene products are assembled into core particles. The latter are present both in the nuclei and in the cytoplasm of hepatocytes, independent of the infecting virus strain. A marked reduction or absence of immunoreactivity, observed with some monoclonal antibodies, was shown to result from nucleotide sequence variations within or close to the corresponding epitope. These results demonstrate that immunoreactive products, derived from the HBV core gene, in the nuclei and cytoplasm of human hepatocytes represent assembled core particles and that monoclonal antibodies with known recognition sites can reveal region-specific core gene variation of the infecting HBV population.

Headache in Sweden: the importance of working conditions.

Headache is a common health problem that causes individual suffering as well as public expense. Because epidemiological studies have shown that headache is most prevalent among persons younger than 55 years, the influence of working conditions is of interest. In this study, we examined the importance of working conditions as a risk factor for frequent headache among the general Swedish population. Data from the Swedish Survey of Living Conditions for the 2-year period, 1988 and 1989, were used. In this survey, a probability sample of the Swedish population aged 16 years and older was interviewed. Frequent headache was defined as a positive answer to the question, "Have you (during the last 2 weeks) had recurrent headache or migraine?" Work stress was studied for two indices: physical work stress and mental work stress. The physical work stress index contained measurements of seven working conditions, and the mental work stress index contained measurements of three working conditions. The proportion of persons who reported frequent headache was greater among women than men, and frequent headache was most common in the age group 25 to 44 years. The logistic regression analyses showed that both physical and mental work stress were strongly associated with frequent headache among both men and women even after controlling for potential confounders. The associations between work stress and frequent headache may be dose-dependent. Heavy mental work stress was most strongly associated with frequent headache among men (odds ratio 3.03 [1.92 to 4.78]) while heavy physical work stress was most strongly associated with frequent headache among women (odds ratio 3.48 [1.13 to 10.65]). Improved working conditions could be one way of preventing headache, thereby decreasing individual suffering and employer as well as public expense.

Hepatitis C virus infection: a possible promoting agent in porphyria cutanea tarda.

The study aimed to differentiate the factors triggering porphyria cutanea tarda, paying special attention to the presumed role of hepatitis C virus infection. In a representative Bulgarian contingent, HCV-antibodies were identified using ELISA II and immunoblot. Seropositivity was significantly higher (p < 0.01) in the sporadic form (36 out of 57 patients; 63.2%) compared with the familiar form (4 out of 20 subjects; 20%). Alcohol abuse was the most common factor preceding the expression of open porphyria both in the sporadic and the familiar forms. In 10 sporadic cases, no precipitating factors were observed, except for the fact that they were anti-HCV positive. In another 2 anti-HCV positive patients, porphyria cutanea tarda was preceded by blood transfusions. Renewed consumption of alcohol after successful treatment was a common reason for relapse, but relapses were most frequent in anti-HCV positive patients (35 relapses in 12 patients), in whom other promoting factors were absent. Analysis of triggering factors shows that most probably hepatitis C virus infection could contribute to the expression of porphyria cutanea tarda and the association of both diseases is not coincidental.

Effects of low molecular weight glycoproteins in chronic hepatitis B.

BACKGROUND/AIMS: We evaluated the effect of low molecular weight glycoproteins isolated from animal spleen (Polyerga) in ten patients with biopsy proven chronic HBV infection with ongoing replication. MATERIAL AND METHODS: Polyerga was given intramuscularly trice weekly and orally 3 tablets daily for 24 weeks. The effect on viral replication was evaluated by measuring HBV-DNA and HBeAg in serum. RESULTS: In three out of ten, HDV-DNA became undetectable and ALT decreased (mean pre-treatment ALT 87.2 +/- 55.38SD, mean post-treatment ALT 62.6 +/- 41.86SD p = 0.026 t-test and Wilcoxon test p = 0.014). During the first month of Polyerga application transient increase of serum ALT was observed in 50%. In HBeAg negative patients and in patients with low pre-treatment level of HBV-DNA (below 250pg/ml) there was significant decrease of ALT by t-test (p = 0.022), Wilcoxon (p = 0.028) and Sign test (p = 0.041) in contrast to those with HBV-DNA above 250pg/ml. CONCLUSION: The effect of increasing the cytolysis shows that these drugs are active, probably by increasing the lymphokine secretion and the generation of cytotoxic T-cells. The absence of side effects, its ability to reduce viral replication and lower ALT activity even in patients with liver cirrhosis warrants further studies as a "second drug" or as a drug of choice when IFN is contraindicated.